Source - LSE Regulatory
RNS Number : 1561A
Nuformix PLC
31 January 2022


Nuformix plc

("Nuformix" or the "Company")


Result of General Meeting


Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, confirms that, further to the announcement made in connection with the Subscription to raise £1.65 million with Lanstead Capital Investors L.P., at the General Meeting held earlier today all Resolutions were passed by way of a poll, the full results of which are given below:



Ordinary/ Special



Total votes cast

No. of votes


No. of votes



THAT, in addition to existing authorities, the directors are authorised to exercise all powers of the Company to allot new ordinary shares









THAT, upon the passing of Resolution 1, the Directors be empowered to allot new ordinary shares for cash on a non-pre-emptive basis.








Accordingly, the Company now has sufficient authorities in place to allot the Second Subscription Shares and the Second Value Payment Shares. The Second Subscription remains conditional on there being no requirement for the Company to publish a prospectus in connection with the Second Subscription. It is expected that the Second Subscription Shares and the Second Value Payment Shares will be issued in April 2022 and at that point application will be made to the London Stock Exchange and the Financial Conduct Authority for Admission.



1.  Any proxy arrangement which gave discretion to the Chairman has been included in the "for" totals.

2.  A "Vote withheld" is not a vote in law and is not counted in the calculation of the percentage of shares voted "For" or "Against" any resolution.

3.  The number of shares in issue at close of business on 28 January 2022 was 615,609,368. The Company does not hold any shares in treasury.


Unless otherwise defined, all capitalised terms used but not defined in this announcement shall have the meaning given to them in the Circular dated 14 January 2022, a copy of which is available to view on the Company's website (




Nuformix plc

via Walbrook

Dr Alastair Riddell, Executive Chairman

Allenby Capital Limited

+44 (0) 20 3328 5656

Nick Athanas / George Payne (Corporate Finance)

Stefano Aquilino / Matt Butlin (Sales and Corporate Broking)

Walbrook PR or +44 (0)20 7933 8780

Anna Dunphy / Phillip Marriage

Tel: +44 (0)7876 741 001 / +44 (0)7867 984 082




About Nuformix


Nuformix is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing. The Company aims to use its expertise in discovering, developing and patenting novel drug forms, with improved physical properties, to develop new products in new indications that are, importantly, differentiated from the original (by way of dosage, delivery route or presentation), thus creating new and attractive commercial opportunities. Nuformix has an early-stage pipeline of preclinical and Phase I-ready assets with potential for significant value and early licensing opportunities.




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account. AJ Bell logo

Related Charts

Nuformix PLC (NFX)

0p (0.00%)
delayed 16:30PM